Literature DB >> 26506874

Meta-analysis of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma.

Yueshu Wang, Wei Ding, Chuang Chen, Zhihao Niu, Ming Pan, Hong Zhang1.   

Abstract

BACKGROUND: With radiotherapy (RT) alone, the five-year overall survival (OS) rate for advanced nasopharyngeal carcinoma (NPC) can only reach 40%, the ratio of distant metastasis (DM) is 36-40%. This meta-analysis was performed to compare the clinical efficacy of concurrent chemoradiotherapy (CCRT) with RT alone in the treatment of locoregionally advanced NPC.
METHODS: The related literature were retrieved and reviewed by two independent investigators from the followed electronic databases: Review manager 5.3 software (Cochrane Collaboration, London, United Kingdom) was applied for statistical analysis.
RESULTS: A total of 16 trials with 2576 patients were recruited according to the criterion. The odds ratios of 3 and 5 years OS was 0.53 (95% confidence interval [95% CI]: 0.44-0.64) and 0.58 (95% CI: 0.48-0.71), which confirmed the significant improvement of CCRT compared with RT alone (P < 0.001). CCRT also reduced the risk of locoregional control failure and DM in locoregionally advanced NPC patients.
CONCLUSIONS: The results suggested that CCRT was more beneficial when compared with RT alone in locoregionally advanced NPC patients. Further study is needed to perform to confirm this effect.

Entities:  

Mesh:

Year:  2015        PMID: 26506874     DOI: 10.4103/0973-1482.168183

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  6 in total

1.  Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.

Authors:  Zhigong Wei; Zhengfang Zhang; Jingwen Luo; Nan Li; Xingchen Peng
Journal:  J Cancer Res Clin Oncol       Date:  2019-05-06       Impact factor: 4.553

2.  Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: a meta-analysis.

Authors:  Yan He; Tao Guo; Hui Guan; Jingjing Wang; Yu Sun; Xingchen Peng
Journal:  Cancer Manag Res       Date:  2018-06-06       Impact factor: 3.989

3.  SIRT6 overexpression induces apoptosis of nasopharyngeal carcinoma by inhibiting NF-κB signaling.

Authors:  Lei Ouyang; Liang Yi; Jingkun Li; Shijiang Yi; Shisheng Li; Peng Liu; Xinming Yang
Journal:  Onco Targets Ther       Date:  2018-11-01       Impact factor: 4.147

4.  The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial.

Authors:  Yanrong Luo; Boning Cai; Bo Li; Fang Liu; Lei Du; Dawei Zhao; Wenjun Fan; Linlin Meng; Xinxin Zhang; Lin Ma
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

5.  MicroRNA-328 inhibits migration and epithelial-mesenchymal transition by targeting CD44 in nasopharyngeal carcinoma cells.

Authors:  Chien-Hung Lin; Ming-Chang Chiang; Yann-Jang Chen
Journal:  Onco Targets Ther       Date:  2018-04-27       Impact factor: 4.147

6.  Induction Chemotherapy Improved Long Term Outcomes in Stage IV Locoregional Advanced Nasopharyngeal Carcinoma.

Authors:  Yu-Wen Wang; Sheng-Yow Ho; Sung-Wei Lee; Chia-Chun Chen; Shieh Litsu; Wen-Tsung Huang; Ching-Chieh Yang; Chia-Hui Lin; Hsuan-Yu Chen; Li-Ching Lin
Journal:  Int J Med Sci       Date:  2020-02-10       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.